Cardiff Oncology, Inc. entered into a securities purchase agreement on July 14, 2026, to sell 8,571,429 shares of common stock and accompanying warrants to institutional investors at $1.05 per share and warrant. Additionally, certain officers and directors purchased 721,649 shares at $1.455 per share. The offering, which closed on July 16, 2026, raised approximately $10.05 million in gross proceeds for working capital and general corporate purposes. Cardiff Oncology is a clinical-stage biotechnology company developing cancer therapies through PLK1 inhibition.